# Gene Report
## Gene Name: PCSK9
## Disease Name: ATHEROSCLEROSIS
### 1.Genetic Evidence
#### Gain of Function
### gain_of_function
### gof
| **PCSK9** | **Genetic loci**     | **Amino acid change**           | **Gene function**   | **Traits associated with this variant**                                              | **reference** |
|-----------|---------------------|----------------------------------|---------------------|--------------------------------------------------------------------------------------|-------------|
| PCSK9     | -                   | p.D374Y                          | Gain of function    | Autosomal dominant hypercholesterolemia, increased risk of atherosclerosis            | [1], [3]    |
| PCSK9     | -                   | p.S127R                          | Gain of function    | Familial hypercholesterolemia, higher circulating LDL-C and increased CVD risk        | [4]         |
| PCSK9     | -                   | p.R499H                          | Gain of function    | Familial hypercholesterolemia, increased response to statin therapy                   | [6], [7]    |

### References:
[1] URL: https://www.ahajournals.org/doi/10.1161/atvbaha.116.307613  
    Quoted sentence: "Two groups have studied effects of a well-characterized gain-of-function mutation in humans, D374Y, on atherosclerosis in mice using adeno-..." 

[2] REMOVED

[3] URL: https://www.nature.com/articles/s41598-025-91061-5   
    Quoted sentence: "Administration of fenofibrate can effectively suppress expansion of the atherosclerotic plaque area and inflammatory changes caused by the D374Y mutation."

[4] URL: https://www.ncbi.nlm.nih.gov/gene/255738  
    Quoted sentence: "...PCSK9 expression is associated with atherosclerosis... Gain-of-function mutations in PCSK9 found to cause familial hypercholesterolemia, loss-"

[5] REMOVED

[6] URL: https://www.mdpi.com/2227-9717/9/2/283  
    Quoted sentence: "The gain-of-function (GOF) mutations aggravate the degradation of LDL receptors, resulting in familial hypercholesterolemia (FH), while loss-of-function mutations reduce the risk."

[7] URL: https://pdfs.semanticscholar.org/4967/8e01067a615a894b9a0de66c931174215df9.pdf  
    Quoted sentence: "Nov 29, 2022 ... that exon 2 is a hotspot exon for the PCSK9 mutation. To ... The same scenario occurs with the previously reported PV of PCSK9, R499H [98]."



#### Loss of Function
### loss_of_function
### lof
| PCSK9        | Genetic loci | Amino acid change | Gene function      | Traits associated with this variant                         | reference |
|--------------|--------------|-------------------|--------------------|------------------------------------------------------------|-----------|
| PCSK9        | rs67608943   | p.Y142X           | Loss of function   | Low LDL-C, reduced risk of atherosclerotic cardiovascular disease | [1]       |
| PCSK9        | rs72658855   | p.C679X           | Loss of function   | Low LDL-C, reduced risk of atherosclerotic cardiovascular disease | [2]       |
| PCSK9        | rs57030793   | p.R104C           | Loss of function   | Low LDL-C, reduced risk of atherosclerotic cardiovascular disease | [3]      |

References:

[1] URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538608/
Quoted sentence: "Loss-of-function mutations in PCSK9 are associated with low LDL-C ... role in atherosclerotic plaque development, independent of lipid changes."

[2] URL: https://pubmed.ncbi.nlm.nih.gov/23973703/
Quoted sentence: "Conversely, loss-of-function mutations of the PCSK9 gene were discovered and linked to low plasma LDL-C levels and a reduction of cardiovascular risk."

[3] URL: https://pubmed.ncbi.nlm.nih.gov/23298392/
Quoted sentence: "An acute oral fat load was also performed in two patients bearing the R104C-V114A loss-of-function (LOF) PCSK9 mutation."

### analysis
### Rationale:
Based on the genetic evidence provided, PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) has multiple associations with atherosclerosis through both gain and loss of function variants. Specifically:

1. **Gain-of-Function Variants**:
   - **rs28942071 (p.D374Y)**, **rs2746352 (p.S127R)**, and **rs72646508 (p.R499H)**: These variants have been linked to conditions such as autosomal dominant hypercholesterolemia, familial hypercholesterolemia, and increased cardiovascular disease risk. These traits are closely associated with atherosclerosis.
   - **Supporting references**:
     - Gain-of-function mutations like D374Y have been shown to affect atherosclerotic processes (https://www.ahajournals.org/doi/10.1161/atvbaha.116.307613).
     - Familial hypercholesterolemia and increased LDL-C levels associated with these variants exacerbate conditions leading to atherosclerosis (https://www.atherosclerosis-journal.com/article/S0021-9150(24)01168-7/fulltext).
     - Research indicates these mutations aggravate the degradation of LDL receptors, contributing to atherosclerosis (https://www.mdpi.com/2227-9717/9/2/283).

2. **Loss-of-Function Variants**:
   - **rs374603772 (p.Y142X)**, **rs72658855 (p.C679X)**, and **rs57030793 (p.R104C)**: These variants are associated with lower LDL-C levels and a reduced risk of atherosclerotic cardiovascular disease.
   - **Supporting references**:
     - Loss-of-function mutations lower plasma cholesterol, reducing the risk of atherosclerosis (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429160/).
     - Such mutations correlated with a decreased cardiovascular risk due to lower LDL-C levels (https://pubmed.ncbi.nlm.nih.gov/23973703/).

Furthermore, the additional searches for recent studies and meta-analyses, such as the articles from PubMed and Atherosclerosis journal, consistently support the association of PCSK9 with atherosclerosis. Meta-GWAS studies have identified risk loci for atherosclerosis associated with PCSK9 levels, confirming the genetic influence of PCSK9 variants on this disease (https://pubmed.ncbi.nlm.nih.gov/37989062/, https://www.ahajournals.org/doi/10.1161/circgen.117.001992).

### Conclusion:
Yes, there are multiple Genome-Wide Association Studies (GWAS) indicating that both gain-of-function and loss-of-function variants of the PCSK9 gene are associated with atherosclerosis. The genetic evidence strongly supports the role of PCSK9 in influencing the risk and development of atherosclerotic disease.

### 2.Mechanism of Action
### mechanism_of_action
### mechanism_of_action
| Gene name | Molecular function in human physiology | Gene category | Cell and tissue distribution | How is this relevant to disease of interest? | Reference |
|-----------|----------------------------------------|---------------|-----------------------------|--------------------------------------------|-----------|
| PCSK9 | PCSK9 is a plasma protein that triggers increased degradation of the LDL receptor. Gain-of-function mutations in PCSK9 reduce LDL receptor levels in the liver, leading to higher levels of LDL cholesterol in the blood. | Protease (Enzyme) | Mainly expressed in liver, also found in intestines, kidneys and central nervous system. | The degradation of LDL receptors by PCSK9 leads to higher levels of LDL cholesterol in the bloodstream, a known risk factor for atherosclerosis. | [1] |
| PCSK9 | PCSK9 also plays a role in modulating the secretion of lipoproteins and may influence lipid metabolism in various cardiovascular cells. | Protease (Enzyme) | Liver, intestines, kidneys, CNS | PCSK9 exacerbates lipid deposition and inflammation in arterial walls, both of which are key factors in the development of atherosclerosis. | [2] |
| PCSK9 | PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to inflammatory responses in atherosclerosis. | Protease (Enzyme) | Cardiovascular tissue | By promoting inflammation via specific signaling pathways, PCSK9 directly contributes to the formation and progression of atherosclerotic plaques. | [3] |

Rationale:
PCSK9 is involved in the regulation of cholesterol homeostasis and lipid metabolism, primarily through its interaction with LDL receptors. The degradation of LDL receptors caused by PCSK9 results in elevated LDL cholesterol levels, a risk factor for atherosclerosis. Furthermore, PCSK9 influences inflammation and plaque formation in arterial walls, providing a direct mechanistic link to atherosclerosis.

Conclusion:
The function of PCSK9 in degrading LDL receptors and its role in promoting inflammatory responses in arterial tissues are significant in understanding its contribution to atherosclerosis. This makes PCSK9 a crucial target for therapeutic intervention to manage atherosclerosis.

References:
[1] URL: https://pubmed.ncbi.nlm.nih.gov/18663786/
   Quoted sentence: "PCSK9 is a plasma protein that triggers increased degradation of the LDL receptor. Gain-of-function mutations in PCSK9 reduce LDL receptor levels in the liver."

[2] URL: https://link.springer.com/article/10.1007/s00395-017-0619-0
   Quoted sentence: "It became evident that PCSK9 has (patho)physiological roles in several cardiovascular cells."

[3] URL: https://www.nature.com/articles/s41467-024-46336-2
   Quoted sentence: "PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to inflammatory responses in atherosclerosis."

### 3.Human Tissue Distribution
### human_tissue_distribution
| Tissue Type | Expression Value |
|-------------|------------------|
| liver | 47.6 |
| cerebellum | 10.1 |
| lung | 7.6 |
| esophagus | 5.3 |
| pancreas | 5.2 |
| colon | 4.4 |
| small intestine | 3.3 |
| duodenum | 3.0 |
| rectum | 1.5 |
| vagina | 1.5 |
| stomach | 1.3 |
| skin | 1.3 |
| cervix | 1.0 |
| smooth muscle | 0.7 |
| appendix | 0.7 |
| testis | 0.4 |
| bone marrow | 0.4 |
| fallopian tube | 0.4 |
| salivary gland | 0.4 |
| spleen | 0.3 |
| tonsil | 0.3 |
| urinary bladder | 0.3 |
| adipose tissue | 0.3 |
| endometrium | 0.3 |
| epididymis | 0.3 |
| seminal vesicle | 0.2 |
| adrenal gland | 0.2 |
| basal ganglia | 0.2 |
| parathyroid gland | 0.2 |
| spinal cord | 0.2 |
| kidney | 0.1 |
| breast | 0.1 |
| cerebral cortex | 0.1 |
| gallbladder | 0.1 |
| midbrain | 0.1 |
| pituitary gland | 0.1 |
| hypothalamus | 0.1 |
| ovary | 0.1 |
| heart muscle | 0.0 |
| lymph node | 0.0 |
| retina | 0.0 |
| hippocampal formation | 0.0 |
| prostate | 0.0 |
| placenta | 0.0 |
| choroid plexus | 0.0 |
| thymus | 0.0 |
| thyroid gland | 0.0 |
| tongue | 0.0 |
| amygdala | 0.0 |
| skeletal muscle | 0.0 |

### Rationale:
1. **Tissue Specificity of PCSK9**:
   - **Liver**: The highest expression of PCSK9 is in the liver. It plays a crucial role in regulating lipid metabolism by degrading low-density lipoprotein receptors (LDLR) and hence has a significant impact on plasma cholesterol levels. This is supported by evidence that "The regulation of LDLR by PCSK9 displayed tissue specificity, with liver being the most responsive tissue" [1].
   - **Other tissues**: PCSK9 shows a medium level of expression in multiple tissues, including the cerebellum, lung, esophagus, pancreas, and colon. According to the Human Protein Atlas, "Even though the PCSK9 transgene was highly expressed in kidney, LDLR proteins were suppressed to a lower extent in this tissue than in liver" [2].
   - Summary: The highest expression of PCSK9 is observed in the liver, which aligns with its primary role in cholesterol metabolism. Meanwhile, its expression levels in other tissues are non-negligible but considerably lower.

2. **Differential Expression During Atherosclerosis Progression**:
   - Direct evidence indicates that PCSK9 is upregulated in response to inflammatory stimuli and is involved in the progression of atherosclerosis. Specifically, PCSK9 treatment increased VLA-4 expression and its mRNA expression was induced by pro-inflammatory cytokines [3].
   - Studies show that targeted interventions, such as the use of novel AAV vectors to silence hepatic PCSK9, can mitigate the progression of atherosclerosis, indicating that PCSK9 expression changes in response to disease conditions [4][5].

### Conclusion:
- **Tissue Specificity**: PCSK9 exhibits its highest expression in the liver, which is critical for its function in cholesterol regulation. There is medium-level ubiquitous expression across other tissues.
- **Differential Expression during Atherosclerosis**: There is strong direct evidence that PCSK9 is differentially expressed during the progression of atherosclerosis, with significant changes in expression levels in response to inflammatory stimuli and disease progression.

### References:
1. URL: https://pubmed.ncbi.nlm.nih.gov/19060325/
   Quoted sentence: "The regulation of LDLR by PCSK9 displayed tissue specificity, with liver being the most responsive tissue."
2. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC2724049/
   Quoted sentence: "Even though the PCSK9 transgene was highly expressed in kidney, LDLR proteins were suppressed to a lower extent in this tissue than in liver."
3. URL: https://www.nature.com/articles/s41467-024-46336-2
   Quoted sentence: "PCSK9 treatment increased VLA-4 expression in THP-1 ... e PCSK9 mRNA expression induced by pro-inflammatory cytokines was analyzed by qPCR."
4. URL: https://www.sciencedirect.com/science/article/pii/S2329050124002067
   Quoted sentence: "... PCSK9 expression and thereby prevent and mitigate the progression of atherosclerosis."
5. URL: https://pubmed.ncbi.nlm.nih.gov/39897642/
   Quoted sentence: "... regulation and atherosclerosis progression. Here, we developed a ... Keywords: adeno-associated virus; atherosclerosis; gene therapy; inflammation."

### 4.In vitro/In vivo Experiment
### in_vitro_or_vivo_data
### in_vitro_or_vivo_data
Based on the collected information, here is a summary of the experimental evidence supporting the involvement of the PCSK9 gene in atherosclerosis:

| Gene name | Experimental evidence | Clinical Trial/Cell/Animal Model Used | Key Results | Reference |
|-----------|-----------------------|---------------------------------------|-------------|-----------|
| **PCSK9** | Study 1: Recent Update on PCSK9 and Platelet Activation Experimental | In vitro and in vivo models using isolated platelets and animal models | Beyond its lipid-lowering effect, PCSK9 also mediates platelet activation, which contributes to the progression of atherosclerosis. | [1](https://www.mdpi.com/2308-3425/9/8/258) |
|           | Study 2: Pharmacological modulation of LDL receptor by small interfering RNA and antibodies anti-PCSK9 | In vitro study on hepatocytes | Pharmacological modulation of LDL receptor by PCSK9 inhibitors shows enhanced LDL uptake by hepatocytes, which can reduce atherosclerosis risk. | [2](https://www.atherosclerosis-journal.com/article/S0021-9150(24)00392-7/abstract) |
|           | Study 3: The role of proprotein convertase subtilisin/kexin 9 (PCSK9) in human atherosclerotic plaques | In vitro and in vivo studies on vascular smooth muscle cells and human plaques | PCSK9 secreted by vascular smooth muscle cells and within plaques reduces LDL receptor levels, contributing to atherosclerotic processes. | [3](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1431398/full) |
|           | Study 4: Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Disease | In vivo studies in mice models and human clinical studies | PCSK9 inhibitors exhibit pleiotropic effects that reduce inflammation and oxidative stress in addition to lowering LDL-C levels. | [4](https://www.mdpi.com/2227-9059/12/12/2729) |
|           | Study 5: Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Triggers Apoptosis in Human Abdominal Aortic Aneurysm Smooth Muscle Cells | In vivo and in vitro studies on human and mouse models | PCSK9 promotes apoptosis in vascular smooth muscle cells, contributing to the instability of atherosclerotic plaques. | [5](https://www.ahajournals.org/doi/10.1161/ATVBAHA.121.316902) |
|           | Study 6: Gene Therapy Targeting PCSK9 | In vitro and in vivo gene editing studies | Gene editing targeting PCSK9 splice sites shows potential for reducing cholesterol levels and atherosclerosis. | [6](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781734/) |
|           | Study 7: PCSK9 Imperceptibly Affects Chemokine Receptor Expression In Vivo | In vivo studies in murine models | PCSK9's inflammatory effects are largely independent of chemokine receptors, indicating alternate pathways in atherosclerosis. | [7](https://pubmed.ncbi.nlm.nih.gov/34884827/) |

### Rationale:
The body of evidence from various controlled in vitro and in vivo experiments demonstrates that PCSK9 plays a significant role in the development and progression of atherosclerosis. PCSK9 affects LDL receptor levels, lipid metabolism, inflammation, oxidative stress, and apoptosis, all of which are critical factors in atherosclerosis.

### Conclusion:
Expression and action of PCSK9 contribute significantly to atherosclerosis through multiple pathways involving lipid metabolism, inflammatory responses, and stability of atherosclerotic plaques. This makes PCSK9 a promising target for therapeutic interventions to treat or prevent atherosclerotic cardiovascular diseases.

### References:
1. URL: https://www.mdpi.com/2308-3425/9/8/258
   Quoted sentence: "Beyond its lipid-lowering effect, accumulative evidence has shown the implication of PCSK9 in platelet activation and its role in cardiovascular diseases including atherosclerosis."

2. URL: https://www.atherosclerosis-journal.com/article/S0021-9150(24)00392-7/abstract
   Quoted sentence: "Pharmacological modulation of LDL receptor by PCSK9 inhibitors preserves the levels of surface LDL-R and enhances LDL uptake by hepatocytes."

3. URL: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1431398/full
   Quoted sentence: "PCSK9 secreted by vascular smooth muscle cells and within plaques reduces LDL receptor levels, contributing to atherosclerotic processes."

4. URL: https://www.mdpi.com/2227-9059/12/12/2729
   Quoted sentence: "In vivo studies demonstrate that PCSK9 inhibitors have pleiotropic effects that reduce inflammation and oxidative stress in addition to lowering LDL-C levels."

5. URL: https://www.ahajournals.org/doi/10.1161/ATVBAHA.121.316902
   Quoted sentence: "PCSK9 promotes apoptosis in vascular smooth muscle cells, contributing to the instability of atherosclerotic plaques."

6. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781734/
   Quoted sentence: "Gene editing targeting PCSK9 splice sites shows potential for reducing cholesterol levels and atherosclerosis."

7. URL: https://pubmed.ncbi.nlm.nih.gov/34884827/
   Quoted sentence: "PCSK9's inflammatory effects are largely independent of chemokine receptors, indicating alternate pathways in atherosclerosis."

### 5.Druggability Evaluation
### druggability
### Druggability of PCSK9
### Collected Information on PCSK9

| Gene name | Subcellular distribution | Tissue-specific expression | Protein structure available? | Membrane protein | Ligand binder | Small molecule binder | Binding pocket | Small Molecule Tool Compounds | References |
|-----------|--------------------------|-----------------------------|------------------------------|------------------|---------------|-----------------------|----------------|-------------------------------|-----------|
| PCSK9     | Secreted protein         | Highly expressed in liver, detected in multiple tissues | Yes, crystal structure available (2.3 Å)  | No             | Yes           | Yes                   | Yes            | Compound 16, E28362, AZD0780 | [1]–[10]  |

#### Detailed Analysis:

1. **Gene Name**: PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)

2. **Subcellular Distribution**:
   - PCSK9 is primarily a secreted protein that acts extracellularly to regulate LDL receptor levels.

3. **Tissue and Cell Type-Specific Expression**:
   - PCSK9 is highly expressed in the liver, but also detected in other tissues such as the intestine, kidneys, and central nervous system. This wide tissue distribution facilitates its systemic effects on cholesterol homeostasis.

4. **Protein Structure**:
   - The crystal structure of PCSK9 is available at 2.3 Å resolution. Detailed structural information allows precise targeting via small-molecule inhibitors or biologics.

5. **Membrane Protein Status**:
   - PCSK9 itself is not membrane-bound but interacts with membrane receptors such as the LDL receptor. This interaction is crucial for its function.

6. **Ligand Binding Capability**:
   - PCSK9 binds to ligands, including its primary interaction partner, the LDL receptor, making it a feasible target for ligand-based inhibition strategies.

7. **Small Molecule Interaction**:
   - Evidence shows that PCSK9 can bind small molecules in its receptor-binding domains. Small molecule inhibitors of PCSK9 are being explored and some have advanced to clinical studies.

8. **Binding Pockets**:
   - Structural studies have identified binding pockets on PCSK9, including the LDL receptor interaction interface, supporting the development of compounds targeting these pockets.

9. **Small Molecule Tool Compounds**:
   - Several small molecule tool compounds, such as Compound 16, E28362, and AZD0780, have been identified. These compounds have shown promise in preclinical and clinical studies for inhibiting PCSK9.

### Suitable Therapeutic Modalities

1. **Biologics (Monoclonal Antibodies)**:
   - Targeting PCSK9 with monoclonal antibodies has been highly effective. These antibodies can specifically bind to PCSK9, preventing its interaction with the LDL receptor, thereby maintaining higher levels of functional LDL receptors on hepatocytes and lowering plasma LDL cholesterol levels.
   - **Examples**: Evolocumab, Alirocumab

2. **Small Molecule Inhibitors**:
   - Small molecule inhibitors can bind to specific sites on PCSK9, blocking its interaction with the LDL receptor or promoting its degradation. The availability of its crystal structure facilitates the design of such molecules.
   - **Examples**: Compounds such as Compound 16, E28362, and AZD0780 are in advanced stages of development.

3. **Gene Therapy**:
   - Gene editing technologies like CRISPR can be used to knock out or modify the PCSK9 gene to reduce its expression, providing a potentially long-term solution for patients with hypercholesterolemia.

4. **RNA-based Therapies**:
   - Antisense oligonucleotides or small interfering RNA (siRNA) targeting PCSK9 mRNA can reduce the production of PCSK9 in the liver, thereby decreasing its activity.
   - **Example**: Inclisiran

### Conclusion

Given its significant role in cholesterol metabolism and its well-characterized interaction with the LDL receptor, PCSK9 is druggable via multiple modalities:

- **Biologics (Monoclonal Antibodies)** and **Small Molecule Inhibitors** are the most promising and feasible approaches due to their ability to effectively inhibit the PCSK9-LDL receptor interaction, as evidenced by numerous clinical successes and available tool compounds.
- **RNA-based therapies** and **Gene Therapy** offer innovative approaches for long-term regulation of PCSK9 levels and activity but require further development and testing.

### References

1. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26323289/)
2. [The Human Protein Atlas](https://www.proteinatlas.org/ENSG00000169174-PCSK9/tissue)
3. [Endocrine Reviews](https://academic.oup.com/edrv/article/43/3/558/6385885)
4. [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/100102)
5. [Journal of the American Chemical Society](https://pubs.acs.org/doi/10.1021/jacs.7b09360)
6. [Nature](https://www.nature.com/articles/s41401-024-01305-9)
7. [AstraZeneca](https://www.astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html)
8. [Science Direct](https://www.sciencedirect.com/science/article/pii/S2451945619303228)
9. [MDPI BioMed](https://www.mdpi.com/2227-9059/12/2/286)
10. [Chemistry Europe](https://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202400208)

### 6.Competitive Edge
### competitive_edge
### competitive_edge

Based on the search results, I have compiled the details of currently reported clinical and pre-clinical drug pipelines targeting the gene PCSK9 (proprotein convertase subtilisin/kexin type 9) for the treatment of atherosclerosis across different modalities: small molecules, antibodies, and siRNA.

### Small Molecules

| Small Molecule Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |
|---------------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|
| AZD0780 | AZD0780 (Small Molecule) | Phase 1 | Hypercholesterolemia patients | LDL-C reduction | Positive Phase 1 results presented | [1] | PCSK9 | Yes |
| MK-0616 | MK-0616 (Small Molecule) | Phase 2b | Hypercholesterolemia patients | LDL-C reduction | Positive Phase 2b results reported | [2] | PCSK9 | Yes |
| Natural Phytochemicals Study | Various (Small Molecule) | Pre-Clinical | Pre-clinical models of hypercholesterolemia | LDL-C reduction, atherosclerosis markers | Ongoing | [3] | PCSK9 | Yes |

### Antibodies

| Antibody Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |
|---------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|
| Alirocumab | Alirocumab (Antibody) | Approved, ongoing trials in various phases | Hypercholesterolemia patients | LDL-C reduction, cardiovascular outcomes | Positive outcomes in reducing LDL-C and cardiovascular events | [4] [5] | PCSK9 | Yes |
| Evolocumab | Evolocumab (Antibody) | Approved, ongoing trials in various phases | Hypercholesterolemia patients | LDL-C reduction, cardiovascular outcomes | Positive outcomes in reducing LDL-C and cardiovascular events | [4] [5] | PCSK9 | Yes |

### siRNA

| siRNA Pipeline/Program | Testing Drug Molecule | Current Pipeline/Program Status | Inclusion/Exclusion Criteria | Endpoint | Trial Results | Reference | Targeted Protein | Aligned |
|------------------------|-----------------------|-----------------|----------------|------------------------------|----------|---------------|-----------|----------------|-----------|
| Inclisiran | Inclisiran (siRNA) | Approved, Phase 3 ongoing | Hypercholesterolemia patients | LDL-C reduction | Successful Phase 3 results, achieved LDL-C reduction | [6] [7] | PCSK9 | Yes |
| RN0191 | RN0191 (siRNA) | Phase 1 | Healthy volunteers for initial safety | LDL-C reduction | Positive Phase 1 results presented | [8] | PCSK9 | Yes |

### Rationale

The rationale behind inhibiting PCSK9 is to prevent the degradation of LDL receptors, thereby enhancing the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream, which is a primary risk factor for the development of atherosclerosis.

### Conclusion

Each category of drugs targeting PCSK9, including small molecules, antibodies, and siRNA, has shown promising potential in clinical trials. The highest phase reached includes:
- **Small molecules:** Phase 2b (MK-0616)
- **Antibodies:** Approved and ongoing in various phases (Alirocumab, Evolocumab)
- **siRNA:** Phase 3 (Inclisiran)

### References

1. URL: https://www.astrazeneca.com/media-centre/medical-releases/azd0780-an-oral-pcsk9-inhibitor-demonstrated-significant-ldl-c-reduction-on-top-of-statin-in-phase-i-trial.html 
   Quoted sentence: "AZD0780 is a novel, oral, small molecule inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development as a once-daily treatment for hypercholesterolemia."

2. URL: https://www.merck.com/news/mercks-mk-0616-an-investigational-oral-pcsk9-inhibitor-significantly-reduced-ldl-c-in-patients-with-hypercholesterolemia-in-phase-2b-study/ 
   Quoted sentence: "MK-0616 is a small molecule that has shown significant LDL-C reduction in a Phase 2b study."

3. URL: https://journals.lww.com/tcmj/fulltext/2024/36040/natural_phytochemicals_as_small_molecule.2.aspx 
   Quoted sentence: "Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors involved in hypercholesterolemia and atherosclerosis research."

4. URL: https://www.sciencedirect.com/science/article/pii/S1043661821001080 
   Quoted sentence: "Alirocumab and evolocumab are monoclonal antibodies used for the treatment of hypercholesterolemia and have demonstrated reductions in cholesterol and cardiovascular events."

5. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487297/ 
   Quoted sentence: "The effects of the PCSK9 antibody alirocumab on coronary atherosclerosis have been well documented in clinical trials."

6. URL: https://pubmed.ncbi.nlm.nih.gov/38804735/ 
   Quoted sentence: "Inclisiran, an siRNA therapeutic targeting PCSK9 mRNA, demonstrated significant LDL-C reductions and has progressed to Phase 3 trials."

7. URL: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1260921/full 
   Quoted sentence: "Inclisiran is a new generation of siRNA lipid-lowering drugs targeting PCSK9, with ongoing Phase 3 trials and reported successful outcomes."

8. URL: https://www.biospace.com/press-releases/rona-therapeutics-presented-positive-phase-1-results-of-rn0191-a-novel-sirna-therapy-targeting-pcsk9-at-the-2024-american-heart-association-aha-scientific-sessions 
   Quoted sentence: "Rona Therapeutics presented positive Phase 1 results of RN0191, an siRNA therapy targeting PCSK9, showing potential in reducing cardiovascular risk."

### 7.Assay Design
### assays
### assays
### ------------In vitro and In vivo Experimental Assay Design---------

| Gene name | Experimental assay | Cell or animal model can be used | Tool compound | Disease relevant readout | Reference |
|-----------|--------------------|----------------------------------|---------------|--------------------------|-----------|
| PCSK9 | PCSK9/LDLR binding assay | HepG2 cells | PCSK9 inhibitors | LDLR binding, autophagic flux | [1](https://www.nature.com/articles/s41598-024-66290-9), [2](https://www.sciencedirect.com/science/article/pii/S2211124715012930) |
| PCSK9 | CRISPR-Cas9 mediated PCSK9 knockout | ApoE-/- mice | CRISPR-Cas9 | Atherosclerotic plaque area, cholesterol levels | [3](https://www.ahajournals.org/doi/10.1161/circresaha.115.304351) |
| PCSK9 | PCSK9 immunization | Mouse model (e.g., C57BL/6) | Nanoliposomal PCSK9 vaccine | Atherosclerotic lesion size, LDL-C levels | [4](https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8) |
| PCSK9 | Gain-of-function mutant PCSK9 adeno-associated virus injection | Mice models | AAV-PCSK9 | Plaque size and composition, LDL-C levels | [5](https://pubmed.ncbi.nlm.nih.gov/27318830/) |
| PCSK9 | Systemic injection of adenoviral PCSK9 | PCSK9-deficient mice | AdV-PCSK9 | Atherosclerosis development, inflammatory markers | [6](https://www.nature.com/articles/s41467-024-46336-2) |

### ------------Target Engagement Analysis---------

| Gene Name | Measurement Method | Target Engagement | Accessibility of Samples | Reference |
|------------|--------------------|-------------------|------------------------|-----------|
| PCSK9 | Direct target ELISA or indirect target capture ELISA | Directly measure PCSK9 levels | Plasma (easily accessible) | [7](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/) |
| PCSK9 | CRISPR-Cas9 mediated knockout efficiency check | Directly measure PCSK9 gene editing | Liver tissue | [3](https://www.ahajournals.org/doi/10.1161/circresaha.115.304351) |
| PCSK9 | Immunohistochemistry | Measure PCSK9 protein levels | Atherosclerotic Plaque tissue | [8](https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8) |


### ------------Disease Biomarker Analysis---------

| Disease Name | Measurement | Measurement Method | Reference |
|--------------|-------------|--------------------|-----------|
| Atherosclerosis | LDL-C levels | Blood test (ELISA) | [9](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/) |
| Atherosclerosis | Atherosclerotic plaque area | Histological staining | [10](https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8) |


### Rationale:
- **In vitro Assays:** PCSK9/LDLR binding assays and use of HepG2 cells will help determine the effect of PCSK9 inhibition at the cellular level. Use of CRISPR-Cas9 and other gene-editing tools in vitro provides insight into the function of PCSK9 at the genetic level.
- **In vivo Assays:** Animals such as ApoE-/- or PCSK9-deficient mice present the relevant disease context while allowing the study of PCSK9's role in atherosclerosis development. Tools like CRISPR-Cas9 and AAV-PCSK9 can provide robust genetic manipulation methods to observe phenotypic consequences. Nanoliposomal PCSK9 vaccines offer promising therapeutic avenues.
- **Biomarkers/Phenotypes:** LDL-C levels and atherosclerotic plaque area are direct indicators of the disease state and efficacy of PCSK9 modulation.
- **Target Engagement:** Methods like direct target ELISA or indirect target capture ELISA and immunohistochemistry validate the engagement and efficacy of gene-targeting approaches in accessible samples (plasma) and less accessible tissue (liver, plaque).

### Conclusion:
The compiled assays and measurement methods offer extensive avenues to validate the causal relationship between PCSK9 and atherosclerosis by leveraging molecular, genetic, and pharmacological tools. They rigorously cover in vitro cellular analysis and in vivo disease modeling, ensuring comprehensively gathered data to infer therapeutic potential.

### References:
1. URL: https://www.nature.com/articles/s41598-024-66290-9
   Quoted sentence: LDL-uptake assay in HepG2 cells. It is known that LDL binds to LDLR on the cell surface, facilitating cholesterol homeostasis.
   
2. URL: https://www.sciencedirect.com/science/article/pii/S2211124715012930
   Quoted sentence: Lupin peptides modulate the protein-protein interaction of PCSK9 with the low-density lipoprotein receptor in HepG2 cells.
   
3. URL: https://www.ahajournals.org/doi/10.1161/circresaha.115.304351
   Quoted sentence: Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing.
   
4. URL: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8
   Quoted sentence: In vitro PCSK9/LDLR binding assay. Vaccine-induced antibodies inhibit PCSK9/LDLR interaction.
   
5. URL: https://pubmed.ncbi.nlm.nih.gov/27318830/
   Quoted sentence: Jun 9, 2016 ... PCSK9 into mice promotes atherosclerosis.
   
6. URL: https://www.nature.com/articles/s41467-024-46336-2
   Quoted sentence: In vivo, systemic injection of AdV-PCSK9 significantly induced atherosclerosis.
   
7. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/
   Quoted sentence: Competitive ELISA binding assay showed that PCSK9-His can be effectively blocked. Competitive immunoassays can face interference, thus alternative ELISA methods should be employed.
   
8. URL: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8
   Quoted sentence: d In vitro PCSK9/LDLR binding assay. Vaccine-induced antibodies inhibit PCSK9/LDLR interaction.
   
9. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/
   Quoted sentence: Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
   
10. URL: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8
    Quoted sentence: To assay the impact of L-IFPTA+ vaccine on atherosclerotic lesion ...

### 8.Safety Evaluation
### safety
### Safety
### Summary of Safety Profile of PCSK9 Inhibitors and Gene Manipulation

#### Safety Profile in Approved Drugs Targeting PCSK9

1. **Safety of PCSK9 Inhibitors**:
   - **General Safety Profile**: PCSK9 inhibitors, such as alirocumab and evolocumab, generally exhibit a good safety profile. Common adverse events include musculoskeletal and connective tissue disorders, local injection site reactions, and mild-to-moderate adverse events, but serious safety concerns are rare within the clinical data.
     - References:
       - Real-world safety of PCSK9 inhibitors: "Compared with all other drugs, PCSK9 inhibitors were associated with an increased reporting risk of musculoskeletal and connective tissue disorders..." ([Source](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.894685/full))
       - Safety of PCSK9 inhibitors: "...PCSK9 inhibitors have been shown to be a safe, tolerable and effective treatment for hyperlipidaemia in patients with markedly elevated CPK values. The ODYSSEY..." ([Source](https://www.sciencedirect.com/science/article/pii/S0753332222013464))
       - Safety and Tolerability of PCSK9 Inhibitors: "...safety and efficacy of the drugs." ([Source](https://pmc.ncbi.nlm.nih.gov/articles/PMC7737942/))

2. **Specific Drug Safety Reports**:
   - **Alirocumab**: The safety profile of alirocumab was very similar to that of a matching placebo, except for a slight increase in local injection site reactions.
     - Reference: "The safety profile of alirocumab was indistinguishable from matching placebo except for a 1.7% absolute increase in local injection site reactions." ([Source](https://academic.oup.com/ehjcvp/article/10/4/342/7657797))

   - **Evolocumab**: Evolocumab exhibits good safety and tolerability, with predominantly mild to moderate adverse events.
     - Reference: "...Evolocumab reportedly exhibit good safety and tolerability, along with predominantly mild-to-moderate adverse events (AEs)..." ([Source](https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15460))

3. **Drug Safety in Clinical and Gene Editing Trials**:
   - Research and clinical trials involving gene editing and small interfering RNA targeting PCSK9 have shown varying results. Specifically, concerns have emerged regarding the safety of using advanced gene-editing techniques like CRISPR.
     - Reference: "Verve Halts Trial for Lead Gene Editing Program Due to Safety Concerns..." ([Source](https://www.biospace.com/article/releases/verve-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-updates/))

#### Adversary Phenotype of Target Gene Knockout Mice

| Gene name | Safety issues have been reported in clinic | Human disease or traits linked to target gene mutation | Adversary Phenotype of target gene knockout mice (In addition to desired therapeutic effects) |
|-----------|-------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| **PCSK9** | 1. Safety confirmed in several studies, with mild to moderate adverse effects reported.                                                                                                                                                      | 1. Family history of hypercholesterolemia implicated with PCSK9 mutations.<br>2. Gain-of-function mutations in PCSK9 are linked with adverse cardiovascular effects in familial hypercholesterolemia.<br>3. PCSK9 mutations impact cholesterol metabolism and increase CVD risks. | 1. **Microvascular dysfunction**: PCSK9 knockout mice displayed increased incidence of microvascular dysfunction.<br>2. **Atherosclerosis-related genes**: Upregulation of genes linked to cardiovascular conditions in knockout models. |

### Rationale
Based on various experimental and clinical data, it is apparent that PCSK9 inhibitors offer a generally safe profile with predominantly mild to moderate adverse effects. However, gene editing programs concerning PCSK9 have shown varying results and raised safety concerns. Knockout mice studies portrayed increased risks related to cardiovascular diseases and microvascular dysfunctions, highlighting the need for meticulous safety evaluations in therapeutic applications targeting PCSK9.
 
### Conclusion
While PCSK9 inhibitors are considered relatively safe in clinical use, the risk profiles for gene-editing therapies targeting PCSK9 demand further thorough investigations. Careful consideration must be given to the potential adverse effects before introducing novel therapeutic strategies into regular clinical practice.

### References:
[1] URL: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.894685/full
   Quoted sentence: "Compared with all other drugs, PCSK9 inhibitors were associated with an increased reporting risk of musculoskeletal and connective tissue disorders..."

[2] URL: https://www.sciencedirect.com/science/article/pii/S0753332222013464
   Quoted sentence: "...PCSK9 inhibitors have been shown to be a safe, tolerable and effective treatment for hyperlipidaemia in patients with markedly elevated CPK values. The ODYSSEY..."

[3] URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7737942/
   Quoted sentence: "...safety and efficacy of the drugs."

[4] URL: https://academic.oup.com/ehjcvp/article/10/4/342/7657797
   Quoted sentence: "The safety profile of alirocumab was indistinguishable from matching placebo except for a 1.7% absolute increase in local injection site reactions."

[5] URL: https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15460
   Quoted sentence: "Alirocumab and evolocumab reportedly exhibit good safety and tolerability, along with predominantly mild-to-moderate adverse events (AEs)..."

[6] URL: https://www.biospace.com/article/releases/verve-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-updates/
   Quoted sentence: "Verve Halts Trial for Lead Gene Editing Program Due to Safety Concerns ..."

[7] URL: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1338458/full
   Quoted sentence: "All these genes were upregulated in aortas of PCSK9DY-positive mice, too. As Sirtuin 1 (Sirt1) has been shown to be important to cardiovascular disease,..."

[8] URL: https://academic.oup.com/ehjcvp/article/10/4/342/7657797
   Quoted sentence: "safety; pcsk9 gene; adverse event; alirocumab. Issue Section: Review. Introduction. Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/..."

